Bertrand Guay / AFP via Getty Images
The European Union and Pfizer-BioNTech have signed an agreement with up to 1.8 billion doses of COVID-19. The bloc’s largest contract to date would cover its entire population, which was a significant advantage in the fight against coronavirus.
The President of the European Commission, Ursula von der Leyen, announced the agreement and tweet, writing is for “900 million guaranteed benefits (+900 million options).”
Other contracts and other vaccine technologies will follow.
– Ursula von der Leyen (@vonderleyen) May 8, 2021
Von der Leyen says more contracts and vaccines are coming for the 27-member bloc, which has a population of about 450 million.
Pfizer-BioNTech’s huge two-dose shot contract would help cover future unknowns, including whether a booster shot will be required and what will happen to the circulating variants.
The agreement requires vaccine production in the EU. Delivery is likely to expand by 2023.
Last month’s commission announced 250 million Pfizer-BioNTech doses will be delivered by June. The EU executive approved the use of the vaccine late last year after the European Medicines Agency issued a permit.
But the virus is still spreading. France, Italy and Spain are currently reports the most cases of COVID-19. In its efforts to reduce transmission, the EU aims to vaccinate 70% of adults.
The Pfizer-BioNTech agreement underlines confidence in the vaccine. As regards Oxford-AstraZeneca, its introduction in the EU has stopped delivery delays and warning about rare blood clots occurring in some recipients.
Approximately 170 million Pfizer-BioNTech vaccines have been delivered in the United States, according to the Center for Disease Control and Prevention, with almost 140 million shots. Three vaccines are allowed for emergency use and almost 60% of the adult population received at least one shot.
The Pfizer-BioNTech vaccine was first approved in the United States in December when it was granted by federal officials emergency use permit.
It is now Pfizer, based in the USA, and its German partner BioNTech requiring full approval in the US, for people over the age of 16, it is a process that requires closer supervision, including the provision of monitoring data six months after vaccination.
The vaccine manufacturer is also I am looking for a permit for emergency use in the US they include children aged 12 to 15.
Reporter Teri Schultz contributed to this report from Brussels.